Century Health Secures $5M Seed to Scale AI-Powered Clinical Data Network

New updates have been reported about Century Health.

Century Health has raised an oversubscribed $5 million seed round to accelerate deployment of its AI platform for real‑world clinical data, positioning the company as a key infrastructure provider for life sciences customers seeking proprietary evidence for drug development. The round was led by Origin Ventures with participation from InnovateHealth Ventures, 25madison, Next Play Ventures, 2048 Ventures, Alumni Ventures, and several strategic clinicians and industry angels, and the capital will be used to deepen pharma collaborations, expand a specialty provider data network, and build out AI-driven data curation capabilities.

At the core of Century Health’s offering is its Century Health Abstraction & Retrieval Model, or CHARM, an AI system that automates extraction and structuring of fragmented clinical data from sources such as electronic health records, clinical notes, and radiology reports, delivering research‑grade real‑world evidence for regulatory and commercial use. CHARM has now achieved 97% accuracy when benchmarked against clinical expert judgment, and Century reports its data network has expanded 60‑fold over the past year across neurology, nephrology, ophthalmology, respiratory, metabolic, and immunology, including partnerships with multiple top‑five global pharmaceutical companies.

The company is targeting a growing bottleneck in AI‑enabled drug discovery and development, where publicly available datasets have been largely tapped out and high‑quality, structured clinical records have become a scarce and strategic asset. By automating traditionally manual abstraction workflows, Century aims to reduce time and cost for tasks such as trial design, patient stratification, outcomes research, and evidence generation for payers, while maintaining the clinical rigor required for regulatory decision‑making.

Management plans to use the new funding to expand disease‑specific registries, enhance CHARM’s capabilities for complex abstraction and data harmonization, and increase coverage across additional specialties and provider groups. Executives and investors frame Century’s role as providing the data substrate for AI models across the drug lifecycle, from discovery and disease modeling to post‑market evidence, positioning the company to benefit from sustained investment in AI for life sciences and from growing demand among pharma, providers, and researchers for reliable, privacy‑conscious real‑world clinical data.